January 31, 2015 1:14 PM ET

Capital Markets

Company Overview of Pershing Square Capital Management, L.P.

Company Overview

Pershing Square Capital Management, L.P is an employee owned hedge fund sponsor. It provides its services to private investment funds. The firm launches and manages hedge funds for its clients. It invests in the public equity and fixed income markets across the globe. The firm employs long/short strategy to make its investments in value stocks. It employs fundamental analysis to create its portfolio. The firm obtains external research to complement its in-house research to make its investments. Pershing Square Capital Management, L.P was founded in 2004 and is based in New York City.

888 Seventh Avenue

42nd Floor

New York, NY 10019

United States

Founded in 2004

Phone:

212-813-3700

Fax:

212-286-1133

Key Executives for Pershing Square Capital Management, L.P.

Chief Executive Officer and Portfolio Manager
Age: 48
Chief Financial Officer
Age: 41
Chief Operating Officer
General Counsel and Chief Compliance Officer
Partner
Age: 47
Compensation as of Fiscal Year 2014.

Pershing Square Capital Management, L.P. Key Developments

Pershing Square Capital Management, L.P. Announces Executive Changes

Pershing Square Capital Management, L.P. announced that Stephen Fraidin, a Senior Partner at Kirkland & Ellis LLP, has joined the firm as Vice Chairman. Mr. Fraidin, a highly regarded mergers and acquisition advisor, has served on Pershing Square’s Board of Advisors since its inception in 2004. Pershing Square also announced the departure of Roy J. Katzovicz, Partner, Chief Legal Officer and Investment Team Member. Following his departure, Mr. Katzovicz will continue to lead public affairs efforts in the investment management industry as part of a newly forming advocacy council. In that capacity, Mr. Katzovicz will advocate the interests of investment firms and their beneficiaries including retirees, public and private pension funds, family offices, universities and charitable endowments.

BOTTINI & BOTTINI, INC. Files Lawsuit on Behalf of Persons Who Sold Allergan Stock Between February 25, 2014 and April 21, 2014

BOTTINI & BOTTINI, INC. announced that a class action has been commenced in the United States District Court for the Central District of California on behalf of persons who sold Allergan, Inc. common stock between February 25, 2014 and April 21, 2014. The complaint charges defendants Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, AGMS, Inc., Pershing Square Capital Management L.P., William A. Ackman, PS Management GP, LLC, and PS Fund 1, LLC with violations of Sections 14(e) and 20A of the Securities Exchange Act of 1934, as amended. Plaintiff alleges that Valeant unlawfully tipped Pershing Square about its plan to make a tender offer for Allergan, with Pershing Square then trading on such material, non-public information by buying an approximately 9.7% stake in Allergan during the Class Period without first disclosing Valeant's plan to pursue a tender offer to acquire Allergan at a significant premium. When Valeant first disclosed its desire to pursue an acquisition of Allergan to the stock market on April 22, 2014, Allergan's stock price soared, rising from a closing price the previous day of $141.88 to close at $163.51 on April 22, 2014 on huge volume of over 32 million shares ten times Allergan's average daily trading volume during the Class Period. Plaintiff seeks to recover damages on behalf of all persons who sold Allergan stock between February 25, 2014 and April 21, 2014, inclusive. Plaintiff alleges that class members were damaged by selling their Allergan stock during the Class Period at prices that did not reflect Valeant's anticipated tender offer to acquire Allergan at a significant premium. The plaintiff is represented by Bottini & Bottini, which specializes in representing investors and has extensive experience in prosecuting securities class actions.

Allergan Announces Lawsuit Against Valeant Pharmaceuticals International, Pershing Square Capital Management and its Principal, William A. Ackman

Allergan commented on the ruling in the United States District Court for the Central District of California in the Company's federal securities litigation against Valeant Pharmaceuticals International, Pershing Square Capital Management and its principal, William A. Ackman. According to a release from Allergan, in the ruling, the Court found that Allergan raised serious questions as to whether Valeant and Pershing Square violated SEC Rule 14e-3, which prohibits trading on the basis of material nonpublic information when an offering person has taken a substantial step or steps to commence a tender offer of a target company. The Court ordered that Valeant and Pershing Square must make 'corrective disclosures to their September 24, proxy solicitation statement in compliance with Section 14(a) of the Securities Exchange Act and Rule 14a-9 promulgated thereunder, including disclosure of the facts underlying Defendants' exposure to liability under Section 14(e) of the Securities Exchange Act and Rule 14e-3 promulgated thereunder.' Allergan commented on the ruling in the United States District Court for the Central District of California in the Company's federal securities litigation against Valeant Pharmaceuticals International, Pershing Square Capital Management and its principal, William A. Ackman. According to a release from Allergan, in the ruling, the Court found that Allergan raised serious questions as to whether Valeant and Pershing Square violated SEC Rule 14e-3, which prohibits trading on the basis of material nonpublic information when an offering person has taken a substantial step or steps to commence a tender offer of a target company. The Court ordered that Valeant and Pershing Square must make 'corrective disclosures to their September 24, proxy solicitation statement in compliance with Section 14(a) of the Securities Exchange Act and Rule 14a-9 promulgated thereunder, including disclosure of the facts underlying Defendants' exposure to liability under Section 14(e) of the Securities Exchange Act and Rule 14e-3 promulgated.

Similar Private Companies By Industry

Company Name Region
Estabrook Advisors LLC United States
Keefe Ventures, LLC United States
Select Capital Corporation United States
Janice Abbott GRAT Trust United States
Q Advisors, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 17, 2014
Allergan Inc.
Merger/Acquisition
November 11, 2014
Zoetis Inc.
Private Placement
September 30, 2014
Platform Specialty Products Corporation
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Pershing Square Capital Management, L.P., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.